1900686-46-5

1900686-46-5 structure

Name: PF-06815345
Chemical Name: (1S)-1-{5-[4-(4-{(3-Chloro-2-pyridinyl)[(3R)-3-piperidinyl]carbamoyl}-2-fluorophenyl)-1-methyl-1H-pyrazol-5-yl]-1H-tetrazol-1-yl}ethyl ethyl carbonate
CAS Number: 1900686-46-5
Molecular Formula: C₂₇H₂₉ClFN₉O₄
Molecular Weight: 598.029
Catalog: Signaling Pathways Metabolic Enzyme/Protease Ser/Thr Protease
Create Date: 2020-01-12 07:44:17
Modify Date: 2024-03-10 19:38:19
PF-06815345 (PF 6815345) is a potent prodrug PCSK9 modulator that inhibits PCSK9 secretion in vitro translation assay; PF-06815345is identified after optimization of the prodrug moiety to maximize intestinal stability achieving liver targeting of the active compound after prodrug turnover by carboxylesterase (CES1). Hypercholesterolemia Phase 1 Discontinued

Name	(1S)-1-{5-[4-(4-{(3-Chloro-2-pyridinyl)[(3R)-3-piperidinyl]carbamoyl}-2-fluorophenyl)-1-methyl-1H-pyrazol-5-yl]-1H-tetrazol-1-yl}ethyl ethyl carbonate
Synonyms	(1S)-1-{5-[4-(4-{(3-Chloro-2-pyridinyl)[(3R)-3-piperidinyl]carbamoyl}-2-fluorophenyl)-1-methyl-1H-pyrazol-5-yl]-1H-tetrazol-1-yl}ethyl ethyl carbonate Carbonic acid, (1S)-1-[5-[4-[4-[[(3-chloro-2-pyridinyl)-(3R)-3-piperidinylamino]carbonyl]-2-fluorophenyl]-1-methyl-1H-pyrazol-5-yl]-1H-tetrazol-1-yl]ethyl ethyl ester

Description	PF-06815345 (PF 6815345) is a potent prodrug PCSK9 modulator that inhibits PCSK9 secretion in vitro translation assay; PF-06815345is identified after optimization of the prodrug moiety to maximize intestinal stability achieving liver targeting of the active compound after prodrug turnover by carboxylesterase (CES1). Hypercholesterolemia Phase 1 Discontinued
References	References 1. McClure KF, et al. Angew Chem Int Ed Engl. 2017 Dec 18;56(51):16218-16222. 2. Daniel Pettersen, et al. Small molecule modulators of PCSK9-a literature and patent overview. Bioorg Med Chem Lett. 2018 Feb 26. pii: S0960-894X(18)30151-3. View Related Products by Target PCSK9 Hypercholesterolemia